Sandoz Sees Aurobindo Deal Collapse As ‘Opportunity’

Termination Of $1bn Deal Will Allow Firm To ‘Optimize US Business’

Sandoz says closing the door on its proposed deal with Aurobindo will open up opportunities for the Novartis subsidiary to optimize its US business, as global sales for Sandoz shot up by around a tenth in the first quarter of 2020 on the back of a COVID-19 boost and a leap of almost a third in Biopharmaceuticals sales.

Two_Doors
As one door closes, another one opens for Sandoz • Source: Shutterstock

Terminating its proposed deal with Aurobindo to divest its US generic oral solids and dermatology units to the Indian firm for around $1bn will provide Sandoz with an “opportunity to optimize the US business,” the Novartis subsidiary believes.

At the start of April, the two firms announced the termination of the deal by mutual consent. (Also see "

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Strategy

More from Business